(MedPage Today) — ORLANDO — Even type 2 diabetes patients with impaired renal function saw improvements in weight and glycemic control with a dual SGLT1/2 inhibitor, according to a meta-analysis.
Among nearly 4,000 adults, those with a baseline…
Source link : https://www.medpagetoday.com/meetingcoverage/aace/115615
Author :
Publish date : 2025-05-16 14:45:00
Copyright for syndicated content belongs to the linked Source.
